Innate Immunity and Leishmania Vaccination Strategies

被引:24
作者
Birnbaum, Ron [1 ]
Craft, Noah [1 ,2 ]
机构
[1] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, LA BioMed, Torrance, CA 90502 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
关键词
Cutaneous leishmaniasis; Vaccine; Immunotherapy; Leishmania; Toll-like receptors; Innate immunity; TOLL-LIKE RECEPTORS; REGULATORY T-CELLS; CUTANEOUS LEISHMANIASIS; VISCERAL LEISHMANIASIS; MAJOR INFECTION; DENDRITIC CELLS; IMMUNOMODULATORS IMIQUIMOD; MURINE MODEL; INTRACELLULAR PATHOGEN; PERSISTENT PARASITES;
D O I
10.1016/j.det.2010.08.014
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Despite the ubiquity and severity of parasitic diseases and our desire to prevent them, there are no effective antiparasitic vaccines in widespread clinical use. This review focuses on strategies for development of a vaccine against cutaneous leishmaniasis as a representative parasitic disease of paramount interest to dermatologists and all who care for patients who live in or travel to the developing world. Any effective strategy will require attention to the central role that host innate immunity plays during induction of durable resistance to these virulent protozoa. The cell types, receptors, and molecules of the innate immune system that will likely play a role in any effective vaccine against cutaneous leishmaniasis are reviewed.
引用
收藏
页码:89 / +
页数:15
相关论文
共 110 条
[1]   Toll-like receptors: critical proteins linking innate and acquired immunity [J].
Akira, S ;
Takeda, K ;
Kaisho, T .
NATURE IMMUNOLOGY, 2001, 2 (08) :675-680
[2]   IL-9 is a susceptibility factor in leishmania major infection by promoting detrimental Th2/type 2 responses [J].
Arendse, B ;
van Snick, J ;
Brombacher, F .
JOURNAL OF IMMUNOLOGY, 2005, 174 (04) :2205-2211
[3]   Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator [J].
Arevalo, I ;
Ward, B ;
Miller, R ;
Meng, TC ;
Najar, E ;
Alvarez, E ;
Matlashewski, G ;
Llanos-Cuentas, A .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (11) :1847-1851
[4]   Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2 [J].
Becker, I ;
Salaiza, N ;
Aguirre, M ;
Delgado, J ;
Carrillo-Carrasco, N ;
Kobeh, LG ;
Ruiz, A ;
Cervantes, R ;
Torres, AP ;
Cabrera, N ;
González, A ;
Maldonado, C ;
Isibasi, A .
MOLECULAR AND BIOCHEMICAL PARASITOLOGY, 2003, 130 (02) :65-74
[5]   Toll-like receptors - sentries in the B-cell response [J].
Bekeredjian-Ding, Isabelle ;
Jego, Gaetan .
IMMUNOLOGY, 2009, 128 (03) :311-323
[6]   CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity [J].
Belkaid, Y ;
Piccirillo, CA ;
Mendez, S ;
Shevach, EM ;
Sacks, DL .
NATURE, 2002, 420 (6915) :502-507
[7]   EFFECTS OF THE IMMUNOMODULATING AGENT R837 ON ACUTE AND LATENT HERPES-SIMPLEX VIRUS TYPE-2 INFECTIONS [J].
BERNSTEIN, DI ;
HARRISON, CJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (09) :1511-1515
[8]   Cellular analysis of cutaneous leishmaniasis lymphadenopathy: Insights into the early phases of human disease [J].
Bomfim, Gloria ;
Andrade, Bruno B. ;
Santos, Silvane ;
Clarencio, Jorge ;
Barral-Netto, Manoel ;
Barral, Aldina .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2007, 77 (05) :854-859
[9]   Pressure Waveform Monitoring During Central Venous Catheterization [J].
Bowdle, Andrew ;
Kharasch, Evan ;
Schwid, Howard .
ANESTHESIA AND ANALGESIA, 2009, 109 (06) :2030-2031
[10]   Dendritic cells in Leishmania infection [J].
Brandonisio, O ;
Spinelli, R ;
Pepe, M .
MICROBES AND INFECTION, 2004, 6 (15) :1402-1409